Compare Capri Holdings Ltd (CPRI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs IDEXX Laboratories, Inc. — how do they compare? Capri Holdings Ltd trades at $15.62 (market cap $1.75B), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 26.4× Capri Holdings Ltd's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Capri Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| CPRI | IDXX | |
|---|---|---|
Market Cap | $1.75B | $46.22B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $766.68 |
52-Week Low | $14.98 | $526.44 |
Enterprise Value | $3.03B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.66, down 65% over five years and near 52-week lows after recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators but faces fundamental challenges including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a net loss of $1.18B last year. Recent Q1 2027 earnings beat expectations with $0.67 EPS versus $0.41 expected, driven by margin improvements and Jimmy Choo growth, though management cut full-year revenue guidance citing Michael Kors weakness.
The investment case hinges on successful execution of the post-Versace turnaround strategy, with the stock trading below consensus price targets offering potential upside if Michael Kors stabilizes. However, significant risks remain including ongoing revenue declines, luxury market softness, and high debt levels requiring careful monitoring of quarterly execution against revised guidance.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
